EHSI announces acquisition of Rotary Cell Culture System

Emerging Healthcare Solutions, Inc. (PinkSheets:EHSI) announced today that it has acquired a Rotary Cell Culture System, or bioreactor, developed using revolutionary NASA research in the field of microgravity.

EHSI's Rotary Cell Culture System^TM, manufactured by Synthecon, is a rotating-wall bioreactor designed to facilitate the growth of human cells in simulated weightlessness. Cell cultures, including stem cells, grown inside the bioreactor look and function much closer to human cells grown within the body than cell cultures grown in Petri dishes.

EHSI expects that this microgravity cellular technology may prove essential to Celulas Genetica's stem-cell research, including its latest endeavor to develop a new medical process known as the Rutherford Procedure.

The Rutherford Procedure is a groundbreaking organ regeneration treatment being developed to utilize proton-beam technology to destroy diseased organ tissue for regeneration using adult stem cells. Celulas Genetica licensed the procedure from the Chinese firm BBFITCL. During the procedure, proton therapy will be used to destroy scar-tissue cells in the liver using high-energy proton beams, a non-invasive treatment proven to minimize damage to healthy tissues and to eliminate the side effects (including nausea) of traditional radiation therapy.

As the scar tissue is systematically destroyed by the proton therapy, a catheter will deliver the patient's own cultured stem cells directly to his or her liver through the bloodstream. As more and more diseased tissue is destroyed, these cultured stem cells could help regenerate the patient's damaged, cirrhotic liver into a healthy, functioning organ once more.

Celulas Genetica purchased a license to develop and market the Rutherford Procedure earlier this week, a day before EHSI announced the company's acquisition. Celulas Genetica will be only the latest outpost in Emerging Healthcare Solutions' global footprint. In addition to its Houston headquarters, the company also maintains business offices in Frankfurt, Germany and Warsaw, Poland.

EHSI invests in technology developed to compete in the stem-cell research industry alongside Amgen (NASDAQ: AMGN), Dendreon Corporation (NASDAQ: DNDN), Smith & Nephew (NYSE: SNN) and Pharmaceutical Product Development (NASDAQ: PPDI).